Andy Batts
Long only, value, growth, momentum

Insmed: A Respiratory Medicine Stock With Upcoming Catalysts

Insmed (NASDAQ:INSM) is an early-stage biotech company focused on the development and commercialization of a game-changer inhaled antibiotic treatment for patients battling serious lung diseases. Its lead product candidate is ARIKACE, an inhaled antibiotic designed to reach directly to the site of serious lung infections.

Insmed's share price is currently hovering around $10.50, and I believe ~70% upside from here is a strong possibility over the medium term. In a public offering of its shares a month ago, the company fixed the share price exactly at this level.

Company Overview

Insmed is primarily engaged in the development and commercialization of ARIKACE (liposomal amikacin for inhalation), which is engineered to deliver a proven and potent anti-infective to improve the

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details